Executive Summary
We took an effective chemotherapy drug and
made it much safer, with no side effects.
Onselex Pharmaceuticals has developed ONX-1006,
a nanoparticle-based cancer treatment designed
to concentrate paclitaxel (PTX), a proven
chemotherapy drug, in tumors while protecting
normal cells.
1. Outstanding Results and Development Goals
-
Continuous Treatment:
One year or longer
of continuous ONX-1006 (PTX)
chemotherapy treatment.
-
Without Side Effects:
Continuous chemotherapy treatment
without side effects,
enabling ongoing tumor cell death.
-
Outstanding Antitumor Efficacy:
20% greater tumor reduction
than Abraxane at the same weekly PTX dose
in a pancreatic cancer animal test.
-
Tumor Elimination Goal:
90–100%.
-
Stage IV Pancreatic Cancer One-Year Survival Goal:
70%.
Treatment duration, tumor elimination, and
survival figures are future clinical
development goals based on preclinical results.
2. Supporting Safety Data
-
Over
30 preclinical studies
and about
4,000 pages
of supporting data.
-
Strong safety findings in repeat-dose
GLP toxicity studies involving rats
and beagle dogs.
-
Beagle dogs, once weekly for 4 weeks:
No Side Effects
at a dose equivalent to about
480 mg PTX
for a 60 kg adult.
-
Female beagle dogs, once weekly for 13 weeks:
No Side Effects
at a dose equivalent to about
320 mg PTX
for a 60 kg adult.
-
2.4 and 1.6 times
a typical 200 mg Abraxane (PTX) dose.
Severe side effects from Abraxane
may require dose reductions or
treatment discontinuation.
3. Supporting Antitumor Efficacy Data
-
Highest level of cancer cell death
in the comparative preclinical study.
-
Prolonged blood circulation and
higher PTX concentrations within tumors.
-
Uses established chemotherapy
anticancer activity.
4. FDA IND Package and SEND Completion
-
November 6, 2026:
Completed the
FDA IND application package
for ONX-1006.
-
15 SEND-applicable studies and
199 electronic datasets:
All successfully passed
Pinnacle 21 validation, a tool used by the U.S. FDA.
-
Estimated U.S. Development Cost:
$1 million or more
to complete an FDA IND application package
and SEND datasets of this scope.
-
Estimated Development Time:
6–9 months
of specialized regulatory preparation.
-
Remaining Major Step:
cGMP clinical manufacturing batch.
Onselex is raising capital to fund
this batch and the first human trial.
The IND has not yet been submitted.
FDA submission will follow completion
of the cGMP clinical batch.
5. Manufacturing Readiness
-
Standardized ONX-1006
manufacturing process.
-
15 kg of nanoparticles
successfully produced.
6. Pancreatic Cancer Market Benchmark
RASONQUE (Daraxonrasib) – Revolution Medicines (RVMD)
-
FDA Approval:
Metastatic pancreatic cancer in eligible adults, August 2026.
-
One Drug, $45 Billion:
Market cap, October 2026.
-
Survival Benefit:
~6.5 months longer vs. chemotherapy.
-
One-Year Survival Rate:
53.2%.
-
Grade ≥3 Treatment-Related Adverse Events:
43.6%.
7. Near-Term Clinical Development
-
Development Roadmap:
cGMP clinical manufacturing →
U.S. FDA IND filing →
South Korea MFDS clinical trial approval →
First clinical trial in South Korea (Cohort 1).
-
Initial Cohort:
Eight treatment-naïve patients with Stage IV
pancreatic cancer in the planned Phase I/IIa clinical trial.
-
U.S. FDA IND Integration:
The South Korea clinical trial is planned to be
included under the U.S. FDA IND, with
clinical trial results to be submitted to the FDA.
For investment or strategic partnership
opportunities, please visit our
Investor & Partner page
and submit the inquiry form.
Company Video:
Watch Company Video
Contact:
CureCancer@OnSelex.com
Executive Summary (PDF)
View the full Executive Summary below,
or open it directly using the link.
View or Download Executive Summary (PDF)
If the PDF does not display in your browser,
use the download link above.